Eli Lilly Scales Back Planned Virginia Insulin Plant
Eli Lilly Scales Back Planned Virginia Insulin Plant
Indianapolis-based Eli Lilly and Co. has halved its planned insulin plant in Prince William County, Virginia, according to a Washington Post report (confirmed by a Lilly spokesperson), which appeared yesterday. The proposed plant is also two years behind schedule.
In a meeting yesterday with the Board of County Supervisors, the Post reported, company officials said they now intend to hire only half the approximately 700 workers originally planned and will reduce the planned 600,000-ft² complex to 300,000 ft². Construction is now expected to begin this winter, and the plant should be fully operational by 2009.
The news report cited increasing costs of steel and other building materials as a major reason for the cutback and the delay in the construction start. Industry analysts linked the decision to erosion in Lilly’s insulin market share and declining sales of one of the company’s insulin products, Humulin.
–Laura Bush
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
